Kairos Pharma, LTD. KAPA
are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in
immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer,
lung cancer, breast cancer, and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies
to treat cancer.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D | $2.1M | $414.0K | $82.0K | — |
| SG&A | $3.4M | $1.9M | $1.6M | — |
| Total operating expenses | $5.6M | $2.3M | $1.7M | — |
| Operating income | -$5.6M | -$2.3M | -$1.7M | — |
| Interest expense | — | $35.0K | $42.0K | — |
| Net income | -$5.4M | -$2.6M | -$1.8M | — |
| EPS, basic | -0.30 | -0.23 | -0.17 | — |
| EPS, diluted | -0.30 | -0.23 | -0.17 | — |
| Shares, diluted (wtd. avg.) | $18.4M | $11.4M | $10.4M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $4.5M | $1.3M | $93.0K | $437.0K |
| Total current assets | $5.4M | $4.2M | $101.0K | — |
| Other intangibles | $62.0K | $222.0K | $382.0K | — |
| Total assets | $6.5M | $5.8M | $965.0K | — |
| Accounts payable | $199.0K | $992.0K | $2.4M | — |
| Total current liabilities | $199.0K | $992.0K | $2.4M | — |
| Total liabilities | — | $992.0K | $3.0M | — |
| Retained earnings | -$14.3M | -$8.8M | -$6.2M | — |
| Total equity | $6.3M | $4.8M | -$2.1M | -$1.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$3.4M | -$4.0M | $81.0K | — |
| Financing cash flow | $6.7M | $5.1M | -$425.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-014159.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |